(KYMR) – Company Press Releases
-
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
-
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
-
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
-
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
-
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
-
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
-
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
-
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
-
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
-
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
-
Kymera Therapeutics Announces Proposed Public Offering
-
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
-
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
-
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
-
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
-
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
-
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
-
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment
-
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
-
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
-
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
-
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
-
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Pay
-
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
-
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
-
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapse
-
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
-
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
-
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
-
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
-
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
-
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
-
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Model
-
Kymera Therapeutics to Participate in Upcoming June Investor Conference
-
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
-
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
-
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
-
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
-
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
-
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
-
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
-
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
-
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
-
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
-
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
-
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
-
X-Chem and Kymera Expand Existing Partnership
-
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
-
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
Back to KYMR Stock Lookup
